The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | The status of CAR T-cell therapy in Brazil and barriers to access
In this video, Nelson Hamerschlak, MD, PhD, Albert Einstein Israelite Hospital, São Paulo, Brazil, comments on the status of CAR T-cell therapy in Brazil, highlighting the availability of commercialized products and the development of academic initiatives but also noting significant barriers to access. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This is an interesting question. You know that in Brazil we have companies that commercialize CAR-T for anti-CD19, Novartis and Kite, and for anti-BCMA Janssen. And also we have a lot of academic initiatives that are mainly in the southeast of the country, but also we have some in other parts of the country. The majority of them are academic programs using or not the project system...
This is an interesting question. You know that in Brazil we have companies that commercialize CAR-T for anti-CD19, Novartis and Kite, and for anti-BCMA Janssen. And also we have a lot of academic initiatives that are mainly in the southeast of the country, but also we have some in other parts of the country. The majority of them are academic programs using or not the project system.
We have now two clinical trials approved in our country. One is the study from University of São Paulo, Ribeirão Preto, and Butantã Institute, and another from my institution, Hospital Israelite Albert Einstein. The first one is mainly for non-Hodgkin lymphoma patients and our study in our institution is a Phase I looking for ALL, lymphoma and also CLL patients. In my hospital, we intended to recruit 30 patients until 2026, until now we have nine patients gone and just one progressive of the disease.
There are a lot of barriers in the access. The main barrier is the cost. So the products, the commercial products are approved by our regulatory agency, Anvisa, but it’s not yet approved for all patients in the country. So some patients could receive the drug by judicializing the process to get the right to be treated.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Lectures to: Kite, Novartis, Janssen; AB: Pfizer.
